BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 17219134)

  • 1. Assessment of quantitative FDG PET data in primary colorectal tumours: which parameters are important with respect to tumour detection?
    Strauss LG; Klippel S; Pan L; Schönleben K; Haberkorn U; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2007 Jun; 34(6):868-77. PubMed ID: 17219134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy.
    Dimitrakopoulou-Strauss A; Strauss LG; Burger C; Rühl A; Irngartinger G; Stremmel W; Rudi J
    J Nucl Med; 2004 Sep; 45(9):1480-7. PubMed ID: 15347714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of chemotherapy outcome in patients with metastatic soft tissue sarcomas based on dynamic FDG PET (dPET) and a multiparameter analysis.
    Dimitrakopoulou-Strauss A; Strauss LG; Egerer G; Vasamiliette J; Schmitt T; Haberkorn U; Kasper B
    Eur J Nucl Med Mol Imaging; 2010 Aug; 37(8):1481-9. PubMed ID: 20336454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy.
    Koukouraki S; Strauss LG; Georgoulias V; Eisenhut M; Haberkorn U; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2006 Oct; 33(10):1115-22. PubMed ID: 16763820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative approaches of dynamic FDG-PET and PET/CT studies (dPET/CT) for the evaluation of oncological patients.
    Dimitrakopoulou-Strauss A; Pan L; Strauss LG
    Cancer Imaging; 2012 Sep; 12(1):283-9. PubMed ID: 23033440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative, dynamic 18F-FDG-PET for the evaluation of soft tissue sarcomas: relation to differential diagnosis, tumor grading and prediction of prognosis.
    Okazumi S; Dimitrakopoulou-Strauss A; Schwarzbach MH; Strauss LG
    Hell J Nucl Med; 2009; 12(3):223-8. PubMed ID: 19936332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of progression-free survival in patients with multiple myeloma following anthracycline-based chemotherapy based on dynamic FDG-PET.
    Dimitrakopoulou-Strauss A; Hoffmann M; Bergner R; Uppenkamp M; Haberkorn U; Strauss LG
    Clin Nucl Med; 2009 Sep; 34(9):576-84. PubMed ID: 19692817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET/CT studies of multiple myeloma using (18) F-FDG and (18) F-NaF: comparison of distribution patterns and tracers' pharmacokinetics.
    Sachpekidis C; Goldschmidt H; Hose D; Pan L; Cheng C; Kopka K; Haberkorn U; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1343-53. PubMed ID: 24562650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PET-FDG as predictor of therapy response in patients with colorectal carcinoma.
    Dimitrakopoulou-Strauss A; Strauss LG; Rudi J
    Q J Nucl Med; 2003 Mar; 47(1):8-13. PubMed ID: 12714949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative studies using positron emission tomography (PET) for the diagnosis and therapy planning of oncological patients.
    Dimitrakopoulou-Strauss A; Strauss L
    Hell J Nucl Med; 2006; 9(1):10-21. PubMed ID: 16617388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of quantitative (18)F-FDG PET studies for the differentiation of malignant and benign bone lesions.
    Dimitrakopoulou-Strauss A; Strauss LG; Heichel T; Wu H; Burger C; Bernd L; Ewerbeck V
    J Nucl Med; 2002 Apr; 43(4):510-8. PubMed ID: 11937595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic PET 18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading.
    Dimitrakopoulou-Strauss A; Strauss LG; Schwarzbach M; Burger C; Heichel T; Willeke F; Mechtersheimer G; Lehnert T
    J Nucl Med; 2001 May; 42(5):713-20. PubMed ID: 11337565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of short-term survival in patients with advanced nonsmall cell lung cancer following chemotherapy based on 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography: a feasibility study.
    Dimitrakopoulou-Strauss A; Hoffmann M; Bergner R; Uppenkamp M; Eisenhut M; Pan L; Haberkorn U; Strauss LG
    Mol Imaging Biol; 2007; 9(5):308-17. PubMed ID: 17623254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early effects of FOLFOX treatment of colorectal tumour in an animal model: assessment of changes in gene expression and FDG kinetics.
    Strauss LG; Hoffend J; Koczan D; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2009 Aug; 36(8):1226-34. PubMed ID: 19280186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation.
    Brush J; Boyd K; Chappell F; Crawford F; Dozier M; Fenwick E; Glanville J; McIntosh H; Renehan A; Weller D; Dunlop M
    Health Technol Assess; 2011 Sep; 15(35):1-192, iii-iv. PubMed ID: 21958472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of response to treatment of unresectable liver tumours with 90Y microspheres: value of FDG PET versus computed tomography.
    Szyszko T; Al-Nahhas A; Canelo R; Habib N; Jiao L; Wasan H; Pagou M; Tait P
    Nucl Med Commun; 2007 Jan; 28(1):15-20. PubMed ID: 17159544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lesion-based detection of early chemosensitivity using serial static FDG PET/CT in metastatic colorectal cancer.
    Buvat I; Necib H; Garcia C; Wagner A; Vanderlinden B; Emonts P; Hendlisz A; Flamen P
    Eur J Nucl Med Mol Imaging; 2012 Oct; 39(10):1628-34. PubMed ID: 22710958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic PET with FDG in patients with unresectable aggressive fibromatosis: regression-based parametric images and correlation to the FDG kinetics based on a 2-tissue compartment model.
    Dimitrakopoulou-Strauss A; Hohenberger P; Pan L; Kasper B; Roumia S; Strauss LG
    Clin Nucl Med; 2012 Oct; 37(10):943-8. PubMed ID: 22899201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment response evaluation with
    Sachpekidis C; Hillengass J; Goldschmidt H; Wagner B; Haberkorn U; Kopka K; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):50-62. PubMed ID: 27573638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of cell-proliferation-associated gene expression on 2-deoxy-2-[(18)f]fluoro-D-glucose (FDG) kinetics as measured by dynamic positron emission tomography (dPET) in colorectal tumors.
    Strauss LG; Koczan D; Klippel S; Pan L; Cheng C; Haberkorn U; Willis S; Dimitrakopoulou-Strauss A
    Mol Imaging Biol; 2011 Dec; 13(6):1290-300. PubMed ID: 21153447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.